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ZnTPPEA as a Potential Photosensitizer in Photodynamic Therapy
Marly Welborn & Dr. Joseph E. Bradshaw
Ouachita Baptist University Department of Chemistry, Arkadelphia, AR 71998-0001

Photodynamic therapy (PDT) is an emerging treatment that
can be utilized against certain types of cancer and other
various diseases. It functions using a photosensitizer in the
presence of light that contributes to cell death in the
desired tissues. This research centered on the development
of a novel water-soluble porphyrin that could be utilized as
one of these photosensitizers. This was achieved by adding
the hydroxyamine, ethanolamine, to the outer portion of
the ZnTPPC core. The resulting compound, ZnTPPEA, was
created using two different synthetic
strategies. Purification was carried out using column
chromatography with Sephadex G-50 followed by Sephadex
LH-20. The desired ZnTPPEA was then characterized
through ultraviolet-visible spectroscopy (UV-vis), nuclear
magnetic resonance (NMR), and infrared spectroscopy (IR),
as well as, the use of high performance liquid
chromatography (HPLC) to determine the purity of the final
product. The ZnTPPEA was tested on the A549 lung cancer
cell line using an MTT assay under light and dark conditions
to assess the compound’s effectiveness as a photosensitizer
for PDT.

• Porphyrin compounds have many uses due to their
conjugated structure, light absorbing qualities, and
ability to act as photosensitizers.
•

Porphyrins are able to perform various functions including
gene regulation, hormone synthesis, oxygen transport
medium (hemoglobin), solar cell (convert light or chemical
energy), as well as potentially treating conditions such as
different forms of cancer, atherosclerosis, rheumatoid
arthritis, macular degeneration, and various autoimmune
diseases.
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• This research specifically investigates the light sensitivity
of the porphyrins and their ability as a photosensitizer.

• Exposure to light resulted in much lower cell viability
when compared to the cells that were kept in the dark
• Cell viability is also affected by concentration of porphyrin.
compound in both light and dark conditions
• The first MTT assay shows that significant cell death began
around 10 μM when cells were exposed to light
• Concentrations were narrowed down between 1—30 μM
in the second MTT assay to investigate where cell viability
was approximately 50%. This value was around a
concentration of 20 μM .
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Infrared Spectroscopy
Reaction 1
• 4-formylbenzoic acid (2) reacted with pyrrole (1) in a propionic
acid solution to form H2TPPC (3).

H2TPPC

Figure 1: Standard Porphyrin
Core Structure
(Unsubstituted)
Figure 2: R-Group
attached to Porphyrin
Core: Ethanolamine

UV-vis Spectroscopy

ZnTPPEA

Nuclear Magnetic Resonance Spectroscopy
Reaction 2
• H2TPPC (3) reacts with zinc chloride in dimethylformamide,
forming an acid chloride porphyrin- ZnTPPC (4).

•

A549 Cell Line
•
•
•
•

Non-small cell lung cancer
Most common type of lung cancer
Represents about 80-85% of lung cancer diagnoses
Its 5 year survival rate is about 25%

ZnTPP-EA

Ethanolamine
Reaction 3
• The acid chloride porphyrin (4) reacts with thionyl chloride
in dimethylformamide to form the acid chloride intermediate (5).

•

High Performance Liquid Chromatography
•
•
•
•
•
•

Photodynamic Therapy
The patient is injected with a photosensitizer after
being diagnosed with a tumor

•

Solvent: 100% acetonitrile
Flow rate: 1.00 mL per minute
Column: Hamilton PRP-1
5 μm 4 x 150 mm
Sample dissolved in H2O
99% pure

•

•

Over time, the photosensitizer collects in the
tumor
The photosensitizer is activated by exposing the
tumor to light for a designated time period

The tumor is selectively destroyed by the
photodynamic therapy treatment

Reaction 4
• The acid chloride intermediate (5) reacts with ethanolamine in
to form ZnTPP-EA, the final product. (6).

•
•
•
•

ZnTPPEA is shown in columns 3-7 on each plate
Living cells are shown by the purple color
The plate on the left was kept in the dark
The plate on the right was exposed to white light
for approximately 26 minutes 18-24 hours after
treatment with the porphyrin compound

•
•

•
•
•
•
•

A novel water-soluble porphyrin was successfully
synthesized.
The compound was characterized by UV-vis, IR, and
NMR spectroscopies as well as high performance
liquid chromatography.
The spectrums show that the correct compound was
formed.
MTT assays showed cell death from concentrations of
1—100 μM when exposed to light but normal cell
growth in dark conditions, making this compound a
legitimate photosensitizer.

Test various versions of porphyrin compound with a
certain wavelength of red light that could become
useful in further development of treatments
Begin in vivo testing of porphyrin compounds with
live animals
Synthesize an unmetylated version of this compound
and test using MTT assays.
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